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Research Paper: Pharmacokinetic Profile of Plasma Le-
vobupivacaine Following Fascia Iliaca Compartment 
Block for Proximal Femoral Fracture in Older Patients
Background: Fascia Iliaca Compartment Block (FICB) is commonly used in older patients 
to provide effective analgesia following hip fracture. 
Objectives: However, only limited Pharmacokinetic (PK) data about levobupivacaine are 
available to help clinical practice and establish safe volumes and amounts of local anesthetics.
Methods: Ten patients aged between 53 and 87 years, who underwent hemiarthroplasty 
following femoral neck fracture were recruited into this study. A fixed volume (40 mL) of 
0.25% levobupivacaine was injected before the induction of anesthesia using ultrasound 
guidance. Venous blood samples were obtained at 0, 10, 20, 30, 45, 60, 75, 90, and 120 min 
time points and analyzed using mass spectrometry.
Results: The median (interquartile range) maximum observed plasma concentration (Cmax) 
of levobupivacaine was 0.48 (0.45-0.61) µg/mL, with the time to reach Cmax (tmax) of 38 
minutes (30–105) after administration, a half-life of 2.8 h (1.65–5.8), and clearance rate of 
0.72 L/min (0.36–1.26). The fixed volume (40 mL) of 0.25% levobupivacaine FICB did not 
exceed the recognized toxic threshold in adults (2.6 µg/mL). 
Conclusion: The data described here indicate a similar levobupivacaine PK profile for older 
patients undergoing FICB for hip arthroplasty compared with the levobupivacaine PK profile 
for the general population. 
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Introduction
ascia iliaca compartment block (FICB) is 
commonly used in older patients to provide 
effective analgesia following a hip frac-
ture [1]. The fascia iliaca compartment is 
a potential space, which contains femoral 
nerve, lateral cutaneous nerve of the thigh, and obturator 
nerve. The local anesthetic, levobupivacaine, has several 
favorable features, including low cardio- and neuro-tox-
icity, high protein binding, and long duration of clinical 
effect [2]. The proximity of the femoral artery and vein 
in the fascia iliaca compartment increases the rapid sys-
temic absorption of local anesthetic, and also increases 
the risk of toxicity. 
Older patients and those with pre-existing cardiac, re-
nal, or hepatic conditions have a higher risk of Local 
Anesthetic Systemic Toxicity (LAST), which can lead 
to cardiac arrest and death. The Pharmacokinetic (PK) 
profile of plasma levobupivacaine in these patients is 
poorly described. This study describes the PK profile of 
levobupivacaine following FICB in patients undergoing 
hip arthroplasty.
Materials and Methods
This study was registered with Research Registry, 
Identifier 229. Following written and informed consent, 
10 patients were recruited to receive FICB before the in-
duction of anesthesia. The inclusion criteria were adult 
patients with a confirmed fractured neck of femur who 
were scheduled to receive FICB as part of their anesthet-
ic care. The patients with contraindications to regional 
anesthesia (The International Normalized Ratio [INR] 
>3, platelets <50000/μL, localized infections), with a 
plasma creatinine >300 µM/L, and or those unable or 
unwilling to give consent were excluded.
An ultrasound-guided FICB with 40 mL of 0.25% 
levobupivacaine was performed using an in-plane ap-
proach. A 22G 50–80 mm insulated long bevel needle 
(StimuplexR) was used to perform the FICB. Subse-
quent anesthetic management was at the discretion of the 
attending anesthetist, with routine care provided as per 
local departmental guidelines for perioperative manage-
ment of these patients. Venous blood samples were taken 
from a dedicated peripheral cannula at 0, 10, 20, 30, 45, 
60, 75, 90, and 120 minutes post FICB. The anonymized 
samples were processed in the laboratory of Scotia Bio-
logics Ltd. The samples were centrifuged (3000 g for 
10 min at 4ºC), and aliquots from the upper layer of the 
resulting plasma fraction were prepared for storage at 
-80°C. The concentration of levobupivacaine from these 
samples was quantified by mass spectrometry. The ana-
lyzed pharmacokinetic parameters included maximum 
observed plasma concentration, time to reach maximal 
concentration, clearance, and half-life. 
Patient plasma analysis
Sample preparation and LC-MS/MS (liquid chroma-
tography with tandem mass spectrometry) analysis were 
performed in the Rowett Institute, University of Aber-
deen. The stock solutions of racemic bupivacaine were 
prepared daily at 3 mg/mL in methanol, with separate 
bupivacaine stock solutions used for the preparation of 
calibration standards and QC (quality control) samples. 
Calibration standards and QC samples were prepared us-
ing human plasma obtained from individuals not given 
levobupivacaine and spiking them with known concen-
trations of bupivacaine in the range 3-3000 ng/mL for 
the calibrants and at 3 ng/mL (low), 90 ng/mL (middle) 
and 2300 ng/mL (high) for the QC samples. The pa-
tients’ samples, calibration standards and QC samples 
(50 µL) were extracted by the addition of 200 µL of 
acetonitrile containing 0.1% formic acid and 500 ng/mL 
D9-bupivacaine (internal standard). After vortex mixing 
and placing on ice for 30 minutes, an equal volume (250 
µL) of 0.1% formic acid was added, and the samples 
were centrifuged. All standard and QC samples were 
analyzed in duplicate. Five microliters of the supernatant 
were injected on to the chromatograph.
Chromatography was performed on an ACE 3µ C18 
(150 x 2.1 mm) column (Hichrom, Reading, UK) main-
tained at 50°C with gradient elution using a mobile phase 
consisting of water (A) and acetonitrile (B) containing 
0.1% formic acid. The gradient started at 30% B, increas-
ing to 100% B over a 3-minute period. This process was 
held for 2 minutes at 100% B before returning to 30% 
B for 4 minutes for re-equilibration, giving a total run 
time of 9 minutes. Bupivacaine and the internal standard 
were eluted with a retention time of 5.1 minutes. MS/
MS analysis was performed using a Thermo Surveyor–
TSQ Quantum (Thermo Scientific, Hemel Hempstead, 
UK) system with electrospray ionization in positive ion 
mode. Flow injection analysis determined the parent and 
product ions (Figure 1) for single reaction monitoring uti-
lizing the following SRM transitions; bupivacaine, m/z 
289.2–140.1 (qualifier), 98.1 (qualifier 1), 84.1 (qualifier 
2), and D9-bupivacaine, m/z 298.2–149.2. Calibration 
curves of concentration versus peak area ratio were plot-
ted and analyzed using weighted least squares or linear 
regression with a weighting of 1/X2 (Figure 2). The lower 
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limit of quantification was 3 ng/mL, and the method was 
fully validated following EMA guidelines [3]. 
Data analysis
The number of patient volunteers included in the study 
was based on previous pharmacokinetic studies on local 
anesthetics [4]. 
Quantification of levobupivacaine in patients’ samples 
was analyzed using the descriptive statistics of the me-
dian (interquartile range) and mean (standard deviation). 
The calculated PK parameters were maximum observed 
bupivacaine plasma concentration (Cmax), time taken to 
reach Cmax (tmax), half-life, and clearance. The median 
concentration of bupivacaine in the patients’ plasma at 
10, 20, 30, 45, 60, 75, 90, and 120 min time points was 
used to determine Cmax and tmax. The equation of the 
exponential line of best fit for each patient data set was 
used to calculate the median concentration at time zero 
(C0) and median elimination rate constant (kel). C0 and 
kel values were used to calculate the median half-life 
(0.693/kel) and clearance ([Dose/C0] x kel).
Results
Ten patients with the median (interquartile range) age 
of 71 (64 - 75) years and weight of 63.5 (57 - 64) kg 
were recruited between August 2017 and February 2018 
(Table 1). Their concentration of levobupivacaine was 
used to calculate the mean levobupivacaine concentra-
tion at each time point (Figure 3). The maximum ob-
served plasma concentration of levobupivacaine (Cmax) 
was calculated for 10, 20, 30, 45, 60, 75, 90, and 120 
min samples for all 10 patients. The PK parameters were 
calculated for each patient, and the median values for the 
cohort are presented in Table 2. 
Discussion
This study describes the pharmacokinetics of levobupi-
vacaine to increase our understanding of the PK profile 
of levobupivacaine in patients undergoing hip arthro-
plasty and FICB under ultrasound control. The data de-
scribed here are consistent with previously reported PK 
studies using different regional anesthetic techniques. 
All analyzed blood samples demonstrated that the plas-
ma levobupivacaine concentrations were below the rec-
ognized toxic concentration of 2.6 µg/mL. No symptoms 
of LAST were reported.
This study used mass spectrometry, an established, ro-
bust technique for post-operative quantification of the 
local anesthetic in plasma [5]. As demonstrated by the 
product ion spectra for bupivacaine and the deuterated 
internal control D9-bupivacaine (Figure 1), although lo-
Figure 1. Parent and product ion spectra for bupivacaine 
A. D9-bupivacaine; B. Obtained using electrospray ionization in positive ion mode
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cal anesthetics can be very close in size and chemistry, 
they can be distinguished from one another by chroma-
tography [6]. The data in this study are in general agree-
ment with the gas chromatography-mass spectrometry 
data described by Odor et al. [7]. Although LC-MS/MS 
is an accurate analytical method, it cannot be used for 
real-time detection of toxic plasma levels of levobupi-
vacaine, as blood sample preparation and running of the 
LC-MS/MS method takes over 8 hours. 
This study’s experimental findings for levobupiva-
caine half-life and clearance in older patients are within 
the range of the recognized parameters for the general 
population [8]. It is expected that the older population 
has a lower hepatic clearance and prolonged half-life of 
Bupivacaine
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Figure 2. Typical calibration curve for the determination of 
bupivacaine in human plasma using weighted least squares 
linear regression with a weighting of 1/X2  (All data points 
represent duplicate analyses.)
Figure 3. Patient plasma bupivacaine concentration over 
time following FICB, Mean±SD; n = 10) patient plasma bu-
pivacaine concentration over 120 min post bupivacaine ad-
ministration (duplicate samples per patient)
Table 1. Demographic profile of study participants
Patient Weight, kg Sex Age, y
1 Not recorded Male 75
2 78 Female 53
3 69.8 Female 79
4 57 Male 58
5 63.5 Female 68
6 53 Male 75
7 58 Female 87
8 52.6 Female 64
9 64 Female 74
10 63.5 Female 68
Median (IQR) 63.5 (57–64) 71 (64–75)
Table 2. Pharmacokinetic profile of study group (Data are given as median [interquartile range])
Pharmacokinetic Parameter Finding
Maximum plasma concentration Cmax 0.483 µg/mL (0.454–0.609)
Time taken to reach Cmax 38 min (30–105)
Half-life 2.8 h (1.65–5.8)
Total plasma clearance 0.72 L/min (0.36–1.26)
Parr R, et al. Plasma Levobupivacaine Following FICB. PBR. 2020; 6(2):151-156.
155
 June 2020. Volume 6. Number 2
lipid-soluble drugs [9]. Surprisingly, this study found a 
little discrepancy between the recognized PK profiles of 
the general population and the older patient group. This 
finding underlines the need for a greater body of plasma 
levobupivacaine pharmacokinetic data for older patients. 
The main limitation of this current study is the small 
sample size. Still, the present data may be pooled in 
combined PK analyses to provide robust evidence of the 
safety of ultrasound-guided FICB in patients undergoing 
hip arthroplasty. 
This study has found FICB a successful and safe tech-
nique for the administration of levobupivacaine to older 
patients. The data from this study have added to the phar-
macokinetic profile of plasma levobupivacaine of older 
patients following FICB for hip fracture surgery. This lo-
cal anesthetic technique was demonstrated to be safe for 
use in older patients supporting previous results [7]. The 
data collected can be used to help local anesthetic dosing 
in older patients and improve local anesthetic safety. 
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